SCHEMBL2970282

SCHEMBL2970282

COC(c1cccc(-n2cnc3cc(/C=N/O)ccc32)c1)c1ccnn1C

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 13/20 0.38
HPGD P15428 2/20 0.37
KDR P35968 1/20 0.35
SRC P12931 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963280 0.86 HPGD (0.37) FGFR1HPGDKDR
SCHEMBL2651746 0.84 FGFR1 (0.39) FGFR1HPGDKDRSRC
SCHEMBL2652694 0.84 HPGD (0.37) FGFR1HPGDKDR
SCHEMBL2653470 0.84 GABRA1 (0.43) FGFR1HPGDKDR
SCHEMBL2651808 0.83 FGFR1 (0.40) FGFR1HPGDKDRSRC
SCHEMBL2977538 0.82 HPGD (0.37) FGFR1HPGDKDR
SCHEMBL2968148 0.82 ALOX5 (0.40) FGFR1HPGDKDR
SCHEMBL2652489 0.81 FGFR1 (0.39) FGFR1HPGDKDRSRC
SCHEMBL2652173 0.78 FGFR1 (0.50) FGFR1HPGD
SCHEMBL2651652 0.75 GABRA1 (0.36) FGFR1HPGDSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US claimed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US claimed
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885HPGD 1855/4885KDR 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.